Kymera Therapeutics (KYMR) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$92.6 million.
- Kymera Therapeutics' Income towards Parent Company fell 2830.96% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 6593.79%. This contributed to the annual value of -$261.9 million for FY2024, which is 5802.23% down from last year.
- Per Kymera Therapeutics' latest filing, its Income towards Parent Company stood at -$92.6 million for Q3 2025, which was down 2830.96% from -$84.7 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Income towards Parent Company registered a high of -$13.2 million during Q1 2021, and its lowest value of -$92.6 million during Q3 2025.
- For the 5-year period, Kymera Therapeutics' Income towards Parent Company averaged around -$49.6 million, with its median value being -$44.9 million (2022).
- As far as peak fluctuations go, Kymera Therapeutics' Income towards Parent Company surged by 4994.96% in 2023, and later tumbled by 31734.15% in 2024.
- Over the past 5 years, Kymera Therapeutics' Income towards Parent Company (Quarter) stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then crashed by 317.34% to -$80.8 million in 2024, then decreased by 14.61% to -$92.6 million in 2025.
- Its last three reported values are -$92.6 million in Q3 2025, -$84.7 million for Q2 2025, and -$74.5 million during Q1 2025.